Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.

Yong Jin KangWon Sik JangJong Kyou KwonCheol Yong YoonJoo Yong LeeWon Sik HamYoung Deuk Choi

Published in: BMC cancer (2017)

Short PSA half-life as well as no response after androgen deprivation is associated with increased risk of treatment failure compared to intermediate PSA half-life.

Keyphrases

radical prostatectomy
prostate cancer
rectal cancer
stem cells
locally advanced
cell therapy
combination therapy